Evaluation of Empirical Antibiotics Appropriateness to Wards for Antibiogram and Clinical Outcome Community Acquired Pneumonia (CAP) in Adults Patients
Abstract
The mortality rate for Community-Acquired Pneumonia (CAP) in Indonesia is in the fourth rank
and the top ten diseases each year. The main therapeutic principle of CAP is the administration of antibiotics.
Improper antibiotic usage can aff ect the success of therapy. The pattern of antibiotics used in hospitals is usually based on clinical and empirical experience, not based on the germ pattern and the sensitivity of antibiotics. The study aims to describe the suitability of empiric antibiotics against the antibiogram profi le and treatment outcomes in inpatients with CAP at PKU Muhammadiyah Gamping Hospital. This study was conducted under the descriptive-analytic observational study design with a retrospective cohort design where the data source came from secondary data, namely the medical records of community pneumonia patients in 2019 and hospital antibiogram data. The data were collected by using the total sampling method. There were 79 community pneumonia patients. The results of the empirical antibiotic suitability test results on antibiograms and clinical outcomes showed that there was no signifi cant relationship between the suitability of empirical antibiotics to the clinical outcome of leukocytes (p = 0.550; RR = 0.725; 95% CI = 0.252-2.086), clinical outcome temperature (p= 0.545; RR = 0.576; 95% CI = 0.049-6.747) and clinical outcome length of stay (p = 0.631; RR = 0.767; CI95= 0.258-2.275). The conclutions there was no signifi cant relationship between the appropriateness of empirical using of antibiotics and antibiogram profi le include leukocyte, temperature and length of stay of the patients (p>0.05).
References
2. Kementrian Kesehatan RI. Profi l Kesehatan Indonesia. Jakarta Pusat; 2013.
3. Rahayu YD, Wahyono D, Mustofa. Evaluasi Rasionalitas Penggunaan Antibiotik Terhadap Luaran Pada
Pasien Anak Penderita Pneumonia. JournalUgmAcId [Internet]. 2014;4(1):264–70. Available from:
https://journal.ugm.ac.id/jmpf/article/view/29473
4. Pratama A. Evaluasi kesesuaian penggunaan antibiotik empiris pada pasien Community Acquired Peumonia
(CAP) Rawat inap di RSUP Dr. Sardjito Yogyakarta serta Antibiogramnya. 2016;
5. Joshi S. Hospital antibiogram: A necessity. Indian J Med Microbiol. 2010;28(4):277–80.
6. Sari MA, Raveinal R, Noverial N. Derajat Keparahan Pneumonia Komunitas pada Geriatri Berdasarkan
Skor CURB-65 di Bangsal Penyakit Dalam RS. Dr. M. Djamil Padang Tahun 2016. J Kesehat Andalas. 2018;7(1):102.
7. Putri RM, Hasan H. Tinjauan Imunologi Pneumonia pada Pasien Geriatri. Cdk-212. 2014;41(1):14–8.
8. López-de-Andrés A, Albaladejo-Vicente R, de Miguel- Diez J, Hernández-Barrera V, Ji Z, Zamorano-
León JJ, et al. Gender diff erences in incidence and in-hospital outcomes of community-acquired, ventilator-
associated and nonventilator hospital-acquired pneumonia in Spain. Int J Clin Pract. 2020;0–1.
9. Almirall J, Serra-Prat M, Bolíbar I, Balasso V. Risk Factors for Community-Acquired Pneumonia in
Adults: A Systematic Review of Observational Studies. Respiration. 2017;94(3):299–311.
10. Jalil ANA. Profi l Pasien Pneumonia Komunitas Rumah Sakit Umum Daerah Cengkareng. Univ Islam Negeri
Syarif Hidayatullah Jakarta. 2015.
11. Worotikan NI, Hasmono D, Kasih E, Ramdani D. Studi Penggunaan Sefalosporin Generasi Ketiga pada
Pasien Pneumonia di Instalasi Rawat Inap Rumah Sakit Umum Haji Surabaya Fakultas Farmasi , Universitas
Katolik Widya Mandala Surabaya , Surabaya , Indonesia Fakultas Farmasi , Universitas Airlangga Suraba.
2019;6(1):66–73.
12. Alfina LNRMR. Analisis Perbandingan Antara Monoterapi dengan Dualterapi Antibiotik Extended
Empiric pada Pasien Community-Acquired Pneumonia di RSUP Fatmawati Jakarta. J Sains Farm Klin
6(2),147–157. 2019;6(2):147–57.
13. Cillóniz C, Polverino E, Ewig S, Aliberti S, Gabarrús A, Menéndez R, et al. Impact of age and comorbidity on
cause and outcome in community-acquired pneumonia. Chest. 2013;144(3):999–1007.
14. Azmi S, Aljunid SM, Maimaiti N, Ali AA, Muhammad Nur A, De Rosas-Valera M, et al. Assessing the
burden of pneumonia using administrative data from Malaysia, Indonesia, and the Philippines. Int J Infect Dis [Internet]. 2016;49:87–93. Available from: http://dx.doi.org/10.1016/j.ijid.2016.05.021
15. Trinh HT, Hoang PH, Cardona-Morrell M, Nguyen HT, Vu DH, Dong PT, Cao TT, Nguyen ST, Pham VT,
Moss L, Dinh K, Dartnell J NH. Antibiotic therapy for inpatients with community-acquired pneumonia in a
developing country. Pharmacoepidemiol Drug Saf. 2, Nguyen HT. Antibiotic therapy for inpatients with
community-acquired pneumonia in a developing country.. ;:. do. Pharmacoepidemiol Drug Saf [Internet]. 24(2):129–36. Available from: https://pubmed.ncbi.nlm.nih.gov/24648269/
16. Faisal F, Burhan E, et. al. Penilaian Respons Pengobatan Empiris pada Pasien Rawat Inap dengan Pneumonia
Komunitas Evaluation of Empirical Treatment Responsse in Hospitalized Patient Community Acquired Pneumonia. J Respir Indo. 2014;34(2):60–70.
17. Capelastegui A, España PP, Bilbao A, Gamazo J, Medel F, Salgado J, et al. Etiology of community-acquired
pneumonia in a population-based study: Link between etiology and patients characteristics, process-of-care,
clinical evolution and outcomes. BMC Infect Dis. 2012;12.
18. Robinson SB, Ernst FR, Lipkin C, Huang X. Patient outcomes on day 4 of intravenous antibiotic therapy
in non-intensive care unit hospitalized adults with community-acquired bacterial pneumonia. Infect Dis Clin Pract. 2014;22(6):320–5.
19. Feri S. Analisis faktor-faktor yang mempengaruhi outcome terapi pasien pneumonia di Rumah Sakit Umum
Pusat Fatmawati Jakarta. 2019;5(3):5–10.
20. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among
adults in Europe. Thorax. 2012;67(1):71–9.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.